Science is making strides in studying the endocannabinoid system in the context of neurodegenerative diseases. Following our review of advances in multiple sclerosis, this installment examines the role of cannabis in Alzheimer’s and Parkinson’s, analyzing current preclinical studies.
In brief
- Neurodegenerative diseases present unique challenges due to the difficulty of regenerating damaged neurons.
- The endocannabinoid system is emerging as a key mechanism in regulating inflammation and oxidative stress in the brain.
- Current evidence is more robust in animal models than in human clinical trials for Alzheimer’s, though results remain promising.
- In Parkinson’s, CBD has shown potential for improving REM sleep symptoms without significant psychoactive effects.
- It is crucial to distinguish between symptomatic efficacy and the ability to slow disease progression in elderly patients.
The challenge of neurodegenerative diseases
Modern medicine has achieved spectacular progress in infection control and surgery, allowing us to treat pathologies that were once fatal. However, when the focus shifts to neurodegenerative diseases, the landscape changes drastically. These conditions, characterized by the progressive loss of functional neurons, represent one of the greatest challenges for the current scientific community.
Unlike other medical fields where technology has enabled the cure or effective control of serious conditions, knowledge regarding the exact causes in this field remains limited. Diseases like Alzheimer’s or Parkinson’s do not have a single identified cause; they are usually multifactorial, involving genetics, age, and unknown environmental factors. Furthermore, the regeneration mechanisms of the central nervous system are inherently slow and complex.
In this context, neuronal destruction is driven by two main processes: excessive chronic inflammation and an increase in oxidative processes that damage cells. The human body loses its natural ability to repair these vital tissues. This is where the endocannabinoid system becomes relevant, presenting itself as a promising avenue for research.
Mechanisms of action: Beyond the psychoactive effect
Cannabinoids—whether produced naturally by the body (endocannabinoids), derived from the plant, or synthesized in a laboratory—interact with receptors located on almost every neuron. This interaction is not limited to producing immediate behavioral changes; it profoundly influences fundamental cellular processes.
Research suggests that these compounds can:
- Regulate the metabolism of glutamate, a neurotransmitter whose excessive excitation can damage neurons (excitotoxicity).
- Enhance the activity of endogenous antioxidant enzymes.
- Inhibit other oxidative molecules that accelerate cellular aging.
- Improve cerebral blood flow and facilitate neuronal regeneration processes.
A distinctive advantage is their ability to cross the blood-brain barrier, acting directly on the brain. This differentiates them from many conventional drugs that fail to effectively reach the areas affected by these pathologies.
Alzheimer’s disease: Amyloid plaques and neuroprotection
Alzheimer’s is the most common cause of dementia worldwide. Its typical clinical manifestation includes a progressive loss of short-term memory, difficulty learning new things, confusion, and language impairment. At the cellular level, the accumulation of plaques formed by beta-amyloid and tau protein tangles is observed.
Research has begun to elucidate how cannabinoids might intervene in this process. A relevant 2014 study by researchers at the Institute of Neuroscience and Physiology at the University of Gothenburg demonstrated that certain cannabinoid compounds, including CBD (cannabidiol) and natural endocannabinoids, could reduce the formation of these toxic plaques and decrease neurotoxicity in cellular models.
Before reaching these in vitro results, animal studies had shown positive effects. In mice genetically modified to develop a pathology similar to human Alzheimer’s, treatment with CBD significantly improved memory, object recognition, and social skills in both the short and long term.
It is important to clarify that these studies have been conducted mostly in cell cultures or animals. Although the results are encouraging, translating these conclusions to human patients requires rigorous clinical trials that are still in development or early stages. The complexity of human disease and individual variability make direct extrapolations premature.
Parkinson’s disease: Movement, sleep, and quality of life
Parkinson’s disease affects the substantia nigra of the brain, causing the death of dopamine-producing neurons. This results in tremors, muscle rigidity, slowness of movement, and balance problems.
Unlike Alzheimer’s, where data are mostly preclinical, there is a more solid base of clinical observation regarding cannabis use in Parkinson’s. Studies conducted in the early 2000s indicated that a significant percentage of patients used cannabis to alleviate symptoms such as tremors or rigidity.
A 2005 controlled clinical trial using oral cannabis extract found no statistically significant differences compared to a placebo in terms of motor symptoms, although the treatment was well tolerated. However, this study used an oral route that is less efficient for the delivery of active cannabinoids compared to other methods.
Subsequent research has focused heavily on CBD due to its safety profile and lack of psychoactive effects. A critical area is REM sleep behavior disorder, where patients suffer from sudden movements during the dream phase. Anecdotal cases and small studies have suggested that high doses of CBD could help regulate this specific symptom.
In a more robust clinical trial with 21 patients, it was observed that while there were no drastic improvements in motor symptoms compared to the placebo, those treated with high doses of CBD reported a notable improvement in quality-of-life scales. This suggests that cannabis could offer holistic benefits beyond simple motor control.
Harm reduction and essential precautions
Despite the therapeutic potential, it is imperative to address current limitations with caution:
- Evidence vs. Promise: Most positive data come from animal models or small human studies. One should not promise a cure or the definitive halting of these complex diseases.
- Risk of falls: Many patients with neurodegenerative conditions are elderly with balance issues. Cannabis can cause hypotension and dizziness, increasing the risk of serious domestic accidents.
- Affected cognition: In advanced stages with severe cognitive impairment, the response to the psychoactive effects of THC can be unpredictable and undesirable.
CBD presents itself as a safer option in this specific context because it does not induce hypotension or significantly alter alertness. Nevertheless, any therapeutic decision must be made under professional medical supervision, evaluating the benefit-risk ratio individually.
Editorial closing
Research on cannabis in neurodegenerative diseases is at a turning point. The properties of the endocannabinoid system to modulate inflammation and protect neurons are scientifically plausible and supported by a growing body of preclinical data.
Psiconáutica.org always maintains a stance based on evidence, critical awareness, and a public health approach. As science advances toward new drugs based on these mechanisms, it is essential that patients and their families inform themselves rigorously, avoiding both premature enthusiasm and unfounded skepticism.
The neuroscience of the future may see combined therapies—leveraging the regenerative capacity of cannabinoids alongside current synthetic treatments—offer new hope to millions of people. Until then, caution and professional support remain the best guides.
